A randomised trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck

This trial is suitable for people that have been diagnosed with an unusual form of melanoma known as neurotropic melanoma. Neurotropic melanoma is characterised by the presence of melanoma cells around nerve sheaths or within nerves. When this type of melanoma is diagnosed on the head or neck region the standard treatment is surgery. This disease may have a high rate of local relapse (recurrence of melanoma in the same area) after surgery. In some hospitals, immediate post-operative radiotherapy is already the standard treatment, but in other hospitals it is not. It is not known for certain whether the benefits of radiotherapy outweigh the risks. The purpose of this trial is to investigate if having radiation therapy soon after surgery is better at preventing the melanoma recurrence than just having surgery alone.

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

50

Closing Date of Accrual

January 2020

Trial Chairperson

A/Prof Matthew Foote, Princess Alexandra Hospital, QLD

Related Post

HeSANDA database for clinical trial data
21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

SMART trial grant
16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed